SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Frostman who wrote (5144)1/30/1998 3:12:00 PM
From: Tunica Albuginea  Read Replies (1) of 23519
 
Frostman, I can't comment factually because I don't know all the details. I would like to leave that to Gene. All I can say is:
-If it is a cream they are delivering to the skin ( which is what I
thought it was all along), it is dead in the water. Won't work,
even if they have a olatinum plated patent on it.
-Delivering a liquid in the urethra they are going uo against
Vivus'patent.
-If delivering Prostaglandin intraurethrally via liquid instead of a
pellet as in MUSE was better, Vivus would have done it.
-what they and Vivus have is the SAME drug: Alprostadil/Prostaglandin.
How can one formulation ( MUSE) cause pain in some patients and the
other, Harvard Scintific, cause none? Doesn't compute.
-Considering the shennanigans going on with HVSF recently ( fired CEO
or CFO because Waite wanted to have money outside of normal
accounting practices ) makes me very suspicious.
As far as goldstein, if he is paid well for his consultacy, why not
take the job/money ( from HVSF ) even if the company flunks later?

TA
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News